Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis

NCT ID: NCT01096472

Last Updated: 2012-07-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-02-28
• Study Completion Date: 2010-06-30

Brief Summary

The aim of this study is to determine the efficacy and safety of a topical application of the combinational cream LAS41003 compared to application of its mono-substances after once daily treatment in patients with inflammatory tinea pedis.

Conditions

Tinea Pedis

Keywords

Tinea pedis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

LAS41003

Once daily

Group Type: EXPERIMENTAL

LAS41003

Intervention Type: DRUG

Once daily

LAS189962

Once daily

Group Type: ACTIVE_COMPARATOR

LAS189962

Intervention Type: DRUG

Once daily

LAS189961

Once daily

Group Type: ACTIVE_COMPARATOR

LAS189961

Intervention Type: DRUG

Once daily

Interventions

LAS41003

Once daily

Intervention Type: DRUG

LAS189961

Once daily

Intervention Type: DRUG

LAS189962

Once daily

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• presence of tinea pedis caused by dermatophytes on one or both feet, characterized by physician's global assessment score of 2 ("notable signs and symptoms exist") or 3 ("prominent signs and symptoms exist") at baseline;
• the physical examination must be without other disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the study;
• female volunteers of childbearing potential must either be surgically sterile (hysterectomy or tubal ligation) or agree to use a reliable method of contraception with a failure rate of less than 1 % per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra uterine devices [IUDs], sexual abstinence or vasectomized partner;
• patients must be willing and able to comply with the requirements of the trial protocol;
• written informed consent obtained.

Exclusion Criteria

• patients with hyperkeratotic chronic plantar tinea pedis (moccasin type);
• receiving systemic therapy with cytotoxic or immunosuppressive drugs either concurrently or within 12 weeks before the baseline visit;
• oral antifungal therapies within three months before study entry (8 months for oral terbinafine), systemic antibiotic or corticosteroid treatment, topical corticosteroids within 30 days before study entry;
• patients with diabetes;
• patients with compromised circulation;
• evidence of drug or alcohol abuse;
• pregnancy or nursing;
• symptoms of a clinically significant illness that may influence the outcome of the study in the four weeks before the treatment phase and during the study;
• participation in the treatment phase of another clinical study within the last four weeks prior to the first administration of investigational drug in this study;
• known allergic reactions to components of the study preparations, hypersensitivity against cetylstearyl alcohol;
• treatment with systemic or locally acting medications which might counter or influence the study aim within two weeks before the treatment phase of the study (e.g. glucocorticosteroids);

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Almirall, S.A.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Christoph Willers, MD, MBA

Role: STUDY_DIRECTOR

Almirall Hermal GmbH

Locations

Investigational Site #2

Berlin, , Germany

Investigational Site #1

Hamburg, , Germany

Countries

Germany

Other Identifiers

2009-016626-14

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

H 552 000-0919

Identifier Type: -

Identifier Source: org_study_id